



Press Release

# Managed Access innovator RareiTi announces its Board of Advisors

Chicago - April 8, 2021

Technology-enabled, data-driven Managed Access company RareiTi is delighted to make public its Advisory Board, a group of accomplished executives providing insight under the leadership of **Jane Griffiths**, former Group Head of Actelion and Company Group Chairman of Janssen EMEA. “RareiTi fills a defined need for a customized approach to the complex challenges of delivering emerging therapies to rare disease patients that are widely dispersed across the globe,” said Griffiths. “I welcome the challenge of working with RareiTi’s executive team to meet this need.”

Joining Griffiths on the Advisory Board are **Martin Andrews**, a pharmaceutical executive with deep experience in drug development and commercialization, most recently as SVP of rare disease for GSK, **Craig DeLarge**, a digital healthcare strategist with global pharma go-to-market expertise and founder of The Digital Mental Health Project, fundamental research focused Palo Alto Investors analyst **Dr. John Doux**, and **Joff Masukawa**, most recently global head of governmental affairs and public relations at Shire and board member of various global NGOs. To read more about the RareiTi Advisory Board, click [here](#).

## About RareiTi

RareiTi offers a new Managed Access model to the pharmaceutical industry delivering solutions to meet the unmet needs of people and communities across the globe impacted by rare disease. Our Managed Access and patient support programs provide care beyond therapy, combining customizable solutions with white glove service. We combine a breadth of global experience, cutting edge technologies and analytics that deliver better outcomes. To find out more, visit [www.rareiti.com](http://www.rareiti.com) or email us at [info@rareiti.com](mailto:info@rareiti.com).